Atlas company financials

PFIZER INC

Standardized 19-year financial series for PFIZER INC, built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0000078003FY2007 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$62.6B

Adjusted EBITDA

—

Net result

$7.8B

Net financial debt

$63.5B

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$16.7B

TTM revenue

$62.7B

TTM free cash flow

—

Latest quarter net result

$3.5B

Quarterly coverage: 53 periods · latest quarter FY2025-Q3 · TTM revenue growth 15.9%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · pfizer-inc-fy2007 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2010-02-26 · Retrieved: 2026-04-26T11:38:48.664374+00:00
SEC EDGAR companyfacts
us-gaap:InterestExpense · us gaap companyfacts · comparative · pfizer-inc-fy2008 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2011-02-28 · Retrieved: 2026-04-26T11:38:48.664374+00:00
SEC EDGAR companyfacts
primary · pfizer-inc-fy2011 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2012-02-28 · Retrieved: 2026-04-26T11:38:48.664374+00:00
SEC EDGAR companyfacts
primary · pfizer-inc-fy2012 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2013-02-28 · Retrieved: 2026-04-26T11:38:48.664374+00:00
SEC EDGAR companyfacts
primary · pfizer-inc-fy2013 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2014-02-28 · Retrieved: 2026-04-26T11:38:48.664374+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2007	48B	—	—	8B	13B	-2B	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing current assets · missing current liabilities · missing ebit · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing research and development · missing total assets
FY2008	48B	—	—	8B	18B	-2B	7B	comparative annual fact carried from later 10k · missing adjusted ebitda · missing ebit · missing gross profit · missing research and development
FY2009	50B	—	—	9B	17B	-1B	41B	missing adjusted ebitda · missing ebit · missing gross profit · missing research and development
FY2010	68B	—	—	8B	11B	-2B	40B	missing adjusted ebitda · missing ebit · missing gross profit · missing research and development
FY2011	67B	—	—	10B	20B	-2B	31B	missing adjusted ebitda · missing ebit · missing gross profit · missing research and development
FY2012	59B	—	—	15B	17B	-1B	26B	missing adjusted ebitda · missing ebit · missing gross profit · missing research and development
FY2013	52B	—	—	22B	18B	-1B	33B	missing adjusted ebitda · missing ebit · missing gross profit · missing research and development
FY2014	50B	—	—	9B	17B	-1B	31B	missing adjusted ebitda · missing ebit · missing gross profit · missing research and development
FY2015

Filing provenance